Outstanding issues delay Orexigen’s naltrexone/bupropion drug approval in Europe

  • July 30, 2014

Orexigen Therapeutics, Inc. today announced its naltrexone/bupropion sustained-release investigational drug application, NB32, has received the Day 180 List of Outstanding Issues from the European Medicines Agency's Committee for Medicinal Products for Human Use.

The naltrexone/bupropion combination drug is intended to treat obesity by promoting weight loss and weight-loss maintenance.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More »
More »
More »
More »
  • Editorial
  • Editor Pick 4
  • Understanding
    vitamin D
  • Nelson Watts, MD, FACP, MACE, CCD, examines the controversy and confusion surrounding Vitamin D.
More »
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »